Raziel Therapeutics Overview

  • Founded
  • 2012

Founded
  • Status
  • Private

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $22.1M

  • Investors
  • 11

Raziel Therapeutics General Information

Description

Developer of injectable drugs created for the decrease of submental fat and fat disorders such as Dercum's disease. The company offers a single injection treatment into subcutaneous fat that causes immediate fat cell death at the injection site, enabling healthcare professionals to provide patients with a significant treatment fat reduction for long time periods without any invasive procedures.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 10 Prof. Menachem Plaut Street
  • Rehovot
  • Israel
+972 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Raziel Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 18-Dec-2019 $22.1M 000.00 0000 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series A) 25-Feb-2016 00.00 00.000 000.00 Completed Clinical Trials - Phase 1
3. Early Stage VC 10-Jul-2015 00.00 00.000 00.000 Completed Clinical Trials - Phase 1
2. Seed Round 01-Dec-2014 $600K $1.19M Completed Clinical Trials - Phase 1
1. Early Stage VC 03-Dec-2012 $589K $589K 00.000 Completed Clinical Trials - Phase 1
To view Raziel Therapeutics’s complete valuation and funding history, request access »

Raziel Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred C 000,000 000.00 000.00 00 000.00 000
Preferred B2 00,000 0000.00 0000.00 00 0000.00 0.000
Preferred B1 00,000 0000.00 0000.00 00 0000.00 0.000
Preferred A2 00,000 000.00 000.00 00 000.00 0.000
Preferred A1 25,000 $16.67 $16.67 1x $16.67 2.61%
Preferred A 75,000 $7.59 $7.59 1x $7.59 3.91%
To view Raziel Therapeutics’s complete cap table history, request access »

Raziel Therapeutics Patents

Raziel Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021213469-A1 Compositions for the treatment of angiolipoma Pending 28-Jan-2020 000000000
AU-2020347539-A1 Compositions for the treatment of solid tumors Pending 15-Sep-2019 0000000000
EP-4031130-A1 Compositions for the treatment of solid tumors Pending 15-Sep-2019 0000000000
US-20220323411-A1 Compositions for the treatment of solid tumors Pending 15-Sep-2019 0000000000
US-20220117935-A1 Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof Pending 15-Jun-2015 A61K31/403
To view Raziel Therapeutics’s complete patent history, request access »

Raziel Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Alon Bloomenfeld Co-Founder, Chief Executive Officer & Board Member
Racheli Gueta Ph.D Clinical Trials Manager
Sharon Cohen-Vered Ph.D Vice President of Chemistry, Manufacturing, And Controls
Eran Blaugrund Ph.D Vice President of Research and Development
Patricia Walker MD Chief Medical Officer & Advisor
You’re viewing 5 of 6 executive team members. Get the full list »

Raziel Therapeutics Board Members (8)

Name Representing Role Since
Adi Goldin Self Board Member 000 0000
Alon Bloomenfeld Raziel Therapeutics Co-Founder, Chief Executive Officer & Board Member 000 0000
Eyal Lifschitz Peregrine Ventures Board Member 000 0000
Philippe Schaison Ph.D Self Chairman 000 0000
Shmuel Cabilly Ph.D Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Raziel Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Catalyst Investments Growth/Expansion Minority 000 0000 000000 0
China Everbright Asset Manager Minority 000 0000 000000 0
Peregrine Ventures Venture Capital Minority 000 0000 000000 0
Quark Venture Venture Capital Minority 000 0000 000000 0
Wille Finance Family Office Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »